被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： 科创板上市公司独立董事提名人声明与承诺 提名人上海凯赛生物技术股份有限公司董事会，现提名吴向 阳女士为上海凯赛生物技术股份有限公司第三届董事会独立董 事候选人，并已充分了解被提名人职业、学历、职称、详细的工 作经历、全部兼职、有无重大失信等不良记录等情况。被提名人 已书面同意出任上海凯赛生物技术股份有限公司第三届董事会 独立董事候选人（参见该独立董事候选人声明）。提名人认为， 被提名人具备独立董事任职资格，与上海凯赛生物技术股份有限 公司之间不存在任何影响其独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 （一）《中华人民共和国公司法》等关于董事任职资格的规 定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和 ...

一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： 科创板上市公司独立董事候选人声明与承诺 本人吴向阳，已充分了解并同意由提名人上海凯赛生物技术 股份有限公司董事会提名为上海凯赛生物技术股份有限公司第 三届董事会独立董事候选人。本人公开声明，本人具备独立董事 任职资格，保证不存在任何影响本人担任上海凯赛生物技术股份 有限公司独立董事独立性的关系，具体声明并承诺如下： （一）《中华人民共和国公司法》等关于董事任职资格的规 定； （二）中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定； （三）其他法律法规、部门规章、规范性文件和上海证券交 易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其直系亲属 和主要社会关系（直系亲属是指配偶、父母、子女等；主要社会 关系是指兄弟姐妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟 姐妹、子女的 ...

提名人上海凯赛生物技术股份有限公司董事会，现提名商建 刚先生为上海凯赛生物技术股份有限公司第三届董事会独立董 事候选人，并已充分了解被提名人职业、学历、职称、详细的工 作经历、全部兼职、有无重大失信等不良记录等情况。被提名人 已书面同意出任上海凯赛生物技术股份有限公司第三届董事会 独立董事候选人（参见该独立董事候选人声明）。提名人认为， 被提名人具备独立董事任职资格，与上海凯赛生物技术股份有限 公司之间不存在任何影响其独立性的关系，具体声明并承诺如下： 科创板上市公司独立董事提名人声明与承诺 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 （三）其他法律法规、部门规章、规范性文件和上海证券交 易所规定的情形。 三、被提名人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其直系亲属 和主要社会关系（直系亲属是指配偶、父母、子女等；主要社会 关系是指兄弟姐妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟 姐妹、子女 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-039 上海凯赛生物技术股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 18 日 至2025 年 8 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年8月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-1 ...

格隆汇8月1日丨凯赛生物(688065.SH)公布，2025年7月31日，公司通过上海证券交易所交易系统以集中 竞价交易方式回购公司股份230,366股,占公司总股本721,289,794股的比例为0.0319%。回购成交的最高 价为53.40元/股，最低价为44.08元/股，支付的资金总额为人民币10,497,716.71元（不含印花税、交易佣 金等交易费用)。 ...

凯赛生物7月31日报收48.10元，较前一交易日下跌2.1%。盘中最高触及49.12元，最低下探47.90元，成 交金额1.56亿元。 7月31日主力资金净流入904.16万元，占流通市值比例为0.03%。从资金流向来看，当日呈现资金净流入 状态。 风险提示：市场有风险，投资需谨慎。 该公司属于化学制品行业，主营业务为生物基材料的研发、生产和销售。作为科创板上市公司，凯赛生 物专注于合成生物学领域的技术创新和产业化应用。 公开信息显示，凯赛生物今年已完成59亿元规模的定向增发，募集资金全部用于补充流动资金和偿还银 行贷款。此次定增规模超过公司IPO融资金额，在年内A股市场40亿元以上规模的定增案例中位居前 列。 ...

Core Viewpoint - The Ministry of Industry and Information Technology of China has officially announced the first batch of "Biomanufacturing Iconic Products," which includes 36 products from various companies, marking a significant step in technological innovation and industrial upgrading in the biomanufacturing sector [1]. Summary by Relevant Sections Biomanufacturing Iconic Products - The list includes 36 companies such as Beijing Shulang Biotechnology, Micro Yuan Synthesis, and Qilu Pharmaceutical, showcasing the diversity and innovation within the biomanufacturing industry [1]. - The products range from biopharmaceuticals to food additives, indicating a broad application of biomanufacturing technologies across different sectors [1]. Notable Products - Ethanol Clostridium protein produced by Beijing Shulang is a feed protein supplement derived from microbial fermentation using industrial waste gases [4]. - Alotose, produced by Micro Yuan Synthesis, is a low-calorie sweetener that enhances production efficiency through microbial fermentation [4]. - Polyhydroxyalkanoate (PHA) from Beijing Microstructure is a biodegradable material that can replace plastics, reducing environmental pollution [4]. - CAR-T cell therapy product, Nakiolun, developed by Huyuan Biotechnology, shows significant advancements in cancer treatment [4]. - Various other products include natural extracts, amino acids, and vaccines, highlighting the innovative approaches in biomanufacturing [4][5][6][7]. Industry Significance - The announcement reflects the government's commitment to promoting the biomanufacturing industry, which is crucial for technological advancement and economic growth [1]. - The diversity of products indicates a growing trend towards sustainable and environmentally friendly manufacturing practices within the industry [1].

Core Viewpoint - The Ministry of Industry and Information Technology of China has officially announced the "First Batch of Iconic Products in Biological Manufacturing," which includes 36 products, marking a significant step in technological innovation and industrial upgrading in the biological manufacturing sector [1][3]. Summary by Sections Iconic Products List - The list includes 36 companies such as: - Shoulang Biotechnology - Micro元合成 - KaiLaiYing - Qinhongdao Huaheng Biotechnology - Qilu Pharmaceutical - JinSai Pharmaceutical - And others [3][5]. Product Details - Each product listed has specific applications and innovations: - **Ethanol Clostridium Protein**: Produced from industrial waste gases, beneficial for animal feed [5]. - **Alotose**: A low-calorie sweetener produced through microbial fermentation, enhancing production efficiency [5]. - **Nakiol Injection**: A CAR-T cell therapy for treating acute lymphoblastic leukemia, showing improved safety and efficacy [5]. - **Vitamin B**: Produced via fermentation, offering higher efficiency compared to traditional extraction methods [7]. - **Recombinant Human Serum Albumin**: Produced using rice cell technology, meeting clinical needs effectively [9]. Industry Significance - The announcement reflects the government's strong emphasis on the development of the biological manufacturing industry, showcasing the potential for innovation and growth in this sector [1][3]. Upcoming Events - The "SynBioCon 2025" conference will be held from August 20-22, focusing on AI in biological manufacturing, green chemistry, and future food and agriculture [11][12].

Group 1 - The core viewpoint of the article emphasizes the rapid development of China's non-grain bio-based materials industry driven by low-carbon transformation and dual carbon strategies, supported by policies and technological advancements [1][18][23] - In 2023, six departments jointly released the "Three-Year Action Plan for Accelerating the Innovative Development of Non-Grain Bio-Based Materials," outlining key goals for 2025 [1][32] - The industry is transitioning from laboratory-scale to large-scale production, with significant projects like the establishment of a 10,000-ton non-grain bio-based rubber production line and a 100,000-ton PLA production line [1][27][23] Group 2 - The non-grain bio-based materials industry is characterized by its use of non-food biomass, which avoids competition with food production and offers sustainable, biodegradable alternatives to traditional petroleum-based materials [7][9][18] - The industry is expected to replace over 30% of grain-based products by 2030, driven by continuous policy support and technological advancements [9][10][18] - The industry is currently in a phase of industrialization breakthroughs, with significant advancements in synthetic biology and CO₂ biomanufacturing technologies [1][27][49] Group 3 - The development of non-grain bio-based materials is crucial for achieving resource security, reducing carbon emissions, and promoting sustainable development [18][19] - The industry has a rich resource endowment, with agricultural waste and forestry residues providing a sustainable raw material supply [40][45] - Technological breakthroughs in synthetic biology and process engineering are accelerating the industrialization of non-grain bio-based materials, enhancing their competitiveness against petroleum-based products [49][50][57]

Overview - The report provides a comprehensive analysis of the synthetic biology industry in China, covering its development status, market trends, and competitive landscape from 2025 to 2031 [1][3]. Industry Definition and Structure - Synthetic biology is defined and categorized, with a detailed breakdown of the industry chain structure and ecosystem [3][4]. - The report includes a regional heat map illustrating the distribution of synthetic biology activities across different areas [3]. Global Development and Trends - The global synthetic biology industry has experienced significant growth, with a focus on policy and technology analysis, including patent applications and key players [4][5]. - Market size and structure are analyzed, highlighting the growth potential in various segments [4][5]. Chinese Market Analysis - The report details the current state of the synthetic biology industry in China, including its historical development and unique characteristics [5][6]. - It discusses the commercial models prevalent in the industry and identifies representative companies [5][6]. Investment and Financing - An analysis of investment trends in the synthetic biology sector reveals significant funding activities and the distribution of investment across different fields [6][7]. - The report summarizes key financing events and the overall investment landscape [6][7]. Competitive Landscape - The competitive dynamics of the synthetic biology industry in China are examined, including the types and numbers of competitors [7][8]. - The report assesses the competitive positioning of leading companies and their strategies for global expansion [7][8]. Technological Development - The report highlights the current state of technology standards in synthetic biology, including ongoing research and development efforts [8][9]. - Key technologies such as gene sequencing and editing are analyzed for their impact on the industry [8][9]. Future Outlook - The report predicts future growth points for the synthetic biology industry, driven by downstream application markets and supportive national policies [9][10]. - It outlines potential investment opportunities and strategic recommendations for stakeholders in the industry [10][11].